Enrollment Completed for Phase 3 Trial Evaluating 1404 Radioactive Imaging Agent

Enrollment Completed for Phase 3 Trial Evaluating 1404 Radioactive Imaging Agent
Progenics Pharmaceuticals has completed enrollment in the Phase 3 study assessing its PSMA-targeted imaging agent 1404 as a tool to identify prostate cancer patients with clinically significant disease. “The results of this large-scale Phase 3 study will provide important insights on the potential of our novel imaging agent to accurately and non-invasively detect and monitor patients with low-grade prostate cancer,” Mark Baker, CEO of Progenics, said in a press re
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *